Biosimilars on the substitution list? Update

In our article published here we informed about the proposal from the Norwegian Ministry of Health and Care Services (“the Ministry”) regarding amendments to the Norwegian Pharmacy Act Section 6-6, suggesting that biosimilars (a biologic medicinal product similar to another already approved biological medicine) may be included on the substitution list.

The public consultation ended September 30, 2020 and the majority of the bodies entitled to comment on the proposal supports the Ministry’s proposed amendments.

The Ministry presented their proposition to the Norwegian Parliament (bill) last week, 16 February, and the Health and Care Committee is appointed to give their report on the amendments within 8 April 2021.

Read more about the proposed amendments in our previously published article.